MINE-R regimen: Difference between revisions

	WikiDoc Resources for MINE-R regimen
Articles
Most recent articles on MINE-R regimen Most cited articles on MINE-R regimen Review articles on MINE-R regimen Articles on MINE-R regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on MINE-R regimen Images of MINE-R regimen Photos of MINE-R regimen Podcasts & MP3s on MINE-R regimen Videos on MINE-R regimen
Evidence Based Medicine
Cochrane Collaboration on MINE-R regimen Bandolier on MINE-R regimen TRIP on MINE-R regimen
Clinical Trials
Ongoing Trials on MINE-R regimen at Clinical Trials.gov Trial results on MINE-R regimen Clinical Trials on MINE-R regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on MINE-R regimen NICE Guidance on MINE-R regimen NHS PRODIGY Guidance FDA on MINE-R regimen CDC on MINE-R regimen
Books
Books on MINE-R regimen
News
MINE-R regimen in the news Be alerted to news on MINE-R regimen News trends on MINE-R regimen
Commentary
Blogs on MINE-R regimen
Definitions
Definitions of MINE-R regimen
Patient Resources / Community
Patient resources on MINE-R regimen Discussion groups on MINE-R regimen Patient Handouts on MINE-R regimen Directions to Hospitals Treating MINE-R regimen Risk calculators and risk factors for MINE-R regimen
Healthcare Provider Resources
Symptoms of MINE-R regimen Causes & Risk Factors for MINE-R regimen Diagnostic studies for MINE-R regimen Treatment of MINE-R regimen
Continuing Medical Education (CME)
CME Programs on MINE-R regimen
International
MINE-R regimen en Espanol MINE-R regimen en Francais
Business
MINE-R regimen in the Marketplace Patents on MINE-R regimen
Experimental / Informatics
List of terms related to MINE-R regimen

VisualWikitext

Latest revision as of 20:27, 30 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: Mesna-Ifosfamide-Novantrone-Etoposide-Rituximab Regimen; MINE-R Regimen

Overview

MINE-R regimen refers to a regimen consisting of mesna, ifosfamide, mitoxantrone, etoposide, and rituximab used to treat relapsed or refractory Hodgkin's lymphoma and non-Hodgkin's lymphoma.^[1]

Regimen

MMesna

IIfosfamide

NMitoxantrone (Novantrone)

EEtoposide

RRituximab

Indications

Hodgkin's lymphoma and non-Hodgkin's lymphoma^[1]

References

↑ ^1.0 ^1.1 Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F; et al. (2003). "Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group". Blood. 101 (2): 420–4. doi:10.1182/blood.V101.2.420. PMID 12509381.

[pmid12509381-1] 1.0 ^1.1 Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F; et al. (2003). "Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group". Blood. 101 (2): 420–4. doi:10.1182/blood.V101.2.420. PMID 12509381.

[1]

@@ Line 6: / Line 6: @@
 ==Overview==
-{{PAGENAME}} refers to a regimen consisting of [[mesna]], [[ifosfamide]], [[mitoxantrone]], [[etoposide]], and [[rituximab]] used to treat relapsed or refractory [[Hodgkin's lymphoma]] and [[Non-Hodgkin's lymphoma]].<ref name="pmid16351801">{{cite journal| author=Fan Y, Huang ZY, Luo LH, Yu HF| title=[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma]. | journal=Ai Zheng | year= 2005 | volume= 24 | issue= 12 | pages= 1503-6 | pmid=16351801 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16351801 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63440&ns=NCI_Thesaurus}}</ref>
+{{PAGENAME}} refers to a regimen consisting of [[mesna]], [[ifosfamide]], [[mitoxantrone]], [[etoposide]], and [[rituximab]] used to treat relapsed or refractory [[Hodgkin's lymphoma]] and [[non-Hodgkin's lymphoma]].<ref name="pmid12509381">{{cite journal| author=Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F et al.| title=Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. | journal=Blood | year= 2003 | volume= 101 | issue= 2 | pages= 420-4 | pmid=12509381 | doi=10.1182/blood.V101.2.420 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12509381  }} </ref>
 ==Regimen==
@@ Line 20: / Line 20: @@
 ==Indications==
-[[Hodgkin's lymphoma]] and [[Non-Hodgkin's lymphoma]]<ref name="pmid16351801">{{cite journal| author=Fan Y, Huang ZY, Luo LH, Yu HF| title=[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma]. | journal=Ai Zheng | year= 2005 | volume= 24 | issue= 12 | pages= 1503-6 | pmid=16351801 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16351801 }} </ref><ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63440&ns=NCI_Thesaurus}}</ref>
+[[Hodgkin's lymphoma]] and [[non-Hodgkin's lymphoma]]<ref name="pmid12509381">{{cite journal| author=Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F et al.| title=Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. | journal=Blood | year= 2003 | volume= 101 | issue= 2 | pages= 420-4 | pmid=12509381 | doi=10.1182/blood.V101.2.420 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12509381  }} </ref>
 ==References==